Physician profile
Jennifer Herbert
NPI 1417077355
$17,162.28
in general payments reported to CMS, 2019-2025
54 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $1,814 · 2021: $3,058 · 2022: $2,690 · 2023: $3,166 · 2024: $2,622 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,240.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,837.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,682.50 | 2019-2025 | |
| Amgen INC. | $1,460.29 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,365.75 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $1,346.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $672.93 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $623.54 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $508.93 | 2019-2025 | Arexvy, Shingrix, Penmenvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $476.99 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $425.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $362.46 | 2019-2024 | Hyqvia, Trintellix, Gammagard |
| Lundbeck LLC | $354.82 | 2021-2025 | Vyepti, Rexulti |
| Allergan, INC. | $279.71 | 2019-2022 | |
| Abbott Laboratories | $273.61 | 2022-2025 | Freestyle Libre 3 |
| Argenx US, INC. | $237.52 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Herbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.